Verastem Oncology, Inc. has received a significant boost from BTIG Research, which upgraded its rating to “strong-buy.” This upgrade, announced on March 4, 2024, comes as analysts pay closer attention to the biopharmaceutical company’s potential in the cancer treatment market.
Several financial institutions have also recently assessed Verastem’s stock. Jefferies Financial Group reaffirmed a “buy” rating with a target price of $19.00, while HC Wainwright initiated coverage with a similar “buy” rating and a price objective of $18.00. Wall Street Zen shifted its stance from “sell” to “hold” on March 7, 2024. In contrast, Weiss Ratings maintained a “sell (d-)” rating as of January 21, 2024. Overall, the stock has received a mix of ratings: three analysts have assigned a “strong buy,” five a “buy,” one a “hold,” and one a “sell.” According to MarketBeat.com, the average rating stands at “buy” with a price target of $16.83.
In its most recent quarterly earnings report, Verastem announced a loss of ($0.50) earnings per share (EPS), slightly below analysts’ expectations of ($0.49). The company reported revenue of $17.54 million, surpassing the forecast of $16.85 million. Analysts predict that Verastem will report an EPS of ($3.02) for the current year.
Insider Activity and Market Movements
Recent insider transactions have drawn attention, particularly involving CEO Dan Paterson and CFO Daniel Calkins. Paterson sold 10,321 shares on January 12, 2024, at an average price of $7.16, totaling $73,898.36. Post-sale, he holds 400,104 shares valued at approximately $2.86 million, marking a decrease of 2.51% in his stake.
CFO Calkins also sold 5,039 shares on the same day for a total of $36,079.24. Following this transaction, Calkins owns 104,719 shares worth about $749,788.04, reflecting a 4.59% decrease in his position. In total, insiders sold 17,678 shares worth $128,685 over the last ninety days, with insiders holding 2.10% of the company’s stock.
Institutional Investments Surge
Verastem has attracted considerable attention from institutional investors, with several hedge funds adjusting their positions. Notably, Polar Capital Holdings Plc increased its stake by 270.7% during the fourth quarter, now holding 3,925,126 shares valued at $30.30 million after acquiring an additional 2,866,350 shares.
Other significant investments include Armistice Capital LLC, which purchased a new stake worth $8.86 million in the second quarter, and Farallon Capital Management LLC, which acquired a new position valued at $15.44 million. Hedge funds and institutional investors collectively own 88.37% of Verastem’s stock, highlighting strong confidence in the company’s future.
Verastem, headquartered in Needham, Massachusetts, specializes in developing small molecule therapies targeting cancer stemness and resistance pathways. The company was founded in 2010 and has made strides in precision medicine aimed at hematologic malignancies and solid tumors. Its lead product, COPIKTRA (duvelisib), is an oral inhibitor of PI3K-delta and PI3K-gamma, which has garnered significant attention in the oncology community.
As Verastem continues to navigate the complexities of the biopharmaceutical landscape, recent upgrades and institutional investments suggest a growing confidence in its capacity to deliver innovative cancer therapies.
